血清肿瘤标志物对晚期NSCLC放疗疗效的评估价值

The Efficacy Evaluation of Serum Tumor Marker in Advanced Non-small Cell Lung Cancer

目的探讨放疗近期疗效与血清肿瘤标志物含量的关系。方法回顾性分析196例晚期非小细胞肺癌(non-small-cell carcinoma,NSCLC)患者放疗前后血清中CEA、CYFAR21-1、SCC、CA125的水平变化,同时通过临床症状等资料评价放疗的近期效果,以此探讨放疗的近期疗效与肿瘤标志物变化的关系。结果 196例患者中有109例在接受放疗后有效,总有效率为55.61%。放疗有效的患者在放疗后常规检查血清中CEA、CYFAR21-1、SCC、CA125含量与放疗前比较,明显减少,且差异具有统计学意义(P<0.05);接受放疗后肿瘤标志物降低组的110例患者近期疗效显著好于升高组,差异具有统计学意义(P<0.05)。结论血清肿瘤标志物CEA、CYFAR21-1、SCC、CA125的含量或可以用来评价放疗对晚期NSCLC的近期效果。

Objective To investigate the relation between short-term efficacy of radiotherapy and serum levels of tumor markers in advanced non-small cell lung cancer before and after radiotherapy in patients with serum CEA,CYFAR21-1,SCC,CA125 levels change. Methods Serum levels of CEA,CYFAR21-1,SCC,CA125 in 196 cases of advanced non-small cell lung cancer patients before and after radiotherapy were retrospectively analyzed. Short-term effects were evaluated by clinical symptoms,and the relationship between the short-term efficacy of radiotherapy and tumor markers changes was investigated. Results Among the 196 patients,109 cases of patients were effective after radiotherapy,the total effective rate was 53. 06%. The routine examination of effective cases showed that serum levels of CEA,CYFAR21-1,SCC,CA125 significantly reduced after radiotherapy,the difference was statistically significant( P < 0. 05); serum levels of CEA,CYFAR21-1,SCC,CA125 significantly reduced after radiotherapy in 110 patients,and their short-term efficacy was better than that those patients with increased serum tumor markers,the difference was statistically significant( P < 0. 05). Conclusion Serum tumor markers CEA,CYFAR21-1,SCC,CA125levels can be used to assess short-term efficacy of patients with advanced NSCLC after radiotherapy.